We used HER2+ breast cancer models of acquired therapeutic resistance to lapatinib established in our laboratory, as previously described [17,18] to investigate how, and to what extent, deregulation of the protein signaling network contributes to therapeutic resistance to HER2/EGFR TKIs. The gene discussed is EGFR; the disease is breast carcinoma.